$1.14/ day, billed weekly
Cancel anytime

(Ads Free, Unlimited access)

NO CREDIT CARD REQUIRED

aTyr Pharma, Inc. (ATYR)ATYR

aTyr Pharma, Inc.

$1.87

Delayed price

PASS

BUY Advisory
Profitable SELL
Loss-Inducing SELL

Profit
Loss
PASS (Skip invest)*

Upturn Stock price based out of last close

Time period over

ALL
YEAR
MONTH
WEEK

Time period over

Upturn Advisory Summary

09/12/2024: ATYR (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Upturns

Type: Stock	Upturn Star Rating	Today’s Advisory: PASS
Profit: -11.79%	Upturn Advisory Performance 1	Avg. Invested days: 18
Profits based on simulation	Stock Returns Performance 1	Last Close 09/12/2024

Type: Stock	Today’s Advisory: PASS
Profit: -11.79%	Avg. Invested days: 18
Upturn Star Rating	Stock Returns Performance 1
Profits based on simulation Last Close 09/12/2024	Upturn Advisory Performance 1

Key Highlights

Company Size ETF	Market Capitalization 0 USD
Price to earnings Ratio -	1Y Target Price -
Dividends yield (FY) -	Basic EPS (TTM) -
Volume (30-day avg) 320127	Beta -
52 Weeks Range 1.42 - 2.50	Updated Date 09/11/2024

Company Size ETF	Market Capitalization 0 USD	Price to earnings Ratio -	1Y Target Price -
Dividends yield (FY) -	Basic EPS (TTM) -	Volume (30-day avg) 320127	Beta -
52 Weeks Range 1.42 - 2.50	Updated Date 09/11/2024

Earnings Date

Report Date -	When -
Estimate -	Actual -

Report Date -

When -

Estimate -

Actual -

Profitability

Profit Margin -

Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -

Return on Equity (TTM) -

Valuation

Trailing PE -	Forward PE -
Enterprise Value -	Price to Sales(TTM) -
Enterprise Value to Revenue -	Enterprise Value to EBITDA -
Shares Outstanding -	Shares Floating -
Percent Insiders -	Percent Institutions -

Trailing PE -	Forward PE -	Enterprise Value -	Price to Sales(TTM) -
Enterprise Value to Revenue -	Enterprise Value to EBITDA -	Shares Outstanding -	Shares Floating -
Percent Insiders -	Percent Institutions -

Analyst Ratings

Rating 4.33	Target Price -	Buy 4
Strong Buy 2	Hold -	Sell -
Strong Sell -

Rating 4.33	Target Price -	Buy 4	Strong Buy 2
Hold -	Sell -	Strong Sell -

About aTyr Pharma, Inc.

Exchange	NASDAQ	Headquaters	San Diego, CA, United States
IPO Launch date	2015-05-07	President, CEO & Director	Dr. Sanjay S. Shukla M.D., M.S.
Sector	Healthcare	Website	https://www.atyrpharma.com
Industry	Biotechnology	Full time employees	56
Headquaters	San Diego, CA, United States
President, CEO & Director	Dr. Sanjay S. Shukla M.D., M.S.
Website	https://www.atyrpharma.com
Website	https://www.atyrpharma.com
Full time employees	56

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

https://www.upturn.io

Disclosure Privacy Policy Terms of Use Sitemap Contact Us

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.